Logo image of PRAX

PRAXIS PRECISION MEDICINES I (PRAX) Stock Analyst Earnings Estimates

NASDAQ:PRAX - Nasdaq - US74006W2070 - Common Stock - Currency: USD

74.49  -5.05 (-6.35%)

After market: 74.49 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032
Revenue
YoY % growth
PRAX revenue by date.PRAX revenue by date.
2.447M1.488M
-39.19%
966.96K
-35.02%
32.623M
3,273.77%
109.46M
235.53%
339.93M
210.55%
724.02M
112.99%
1.193B
64.77%
1.507B
26.32%
1.833B
21.63%
EBITDA
YoY % growth
PRAX ebitda by date.PRAX ebitda by date.
-167.15M
-169.95%
-213.57M
-27.77%
-125.941M
41.03%
-198.702M
-57.77%
-252.354M
-27.00%
-292.594M
-15.95%
-279.419M
4.50%
-137.285M
50.87%
24.113M
117.56%
297.54M
1,133.94%
521.14M
75.15%
649.39M
24.61%
EBIT
YoY % growth
PRAX ebit by date.PRAX ebit by date.
-167.33M
-170.02%
-213.99M
-27.89%
-126.373M
40.94%
-197.815M
-56.53%
-252.273M
-27.53%
-263.867M
-4.60%
-200.21M
24.12%
-131.141K
99.93%
349.4M
266,529.98%
805.45M
130.52%
1.121B
39.18%
1.412B
25.96%
Operating Margin
PRAX operating margin by date.PRAX operating margin by date.
N/AN/A-5,164.41%-13,294.01%-26,089.27%-808.84%-182.91%-0.04%48.26%67.51%74.39%77.03%
EPS
YoY % growth
PRAX eps by date.PRAX eps by date.
-3.89
93.23%
-16.84
-332.90%
-23.67
-40.56%
-10.30
56.47%
-11.93
-15.80%
-12.00
-0.60%
-9.89
17.58%
-2.16
78.16%
12.32
670.08%
29.40
138.72%
33.41
13.62%
34.87
4.38%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25 Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth
-2.90
2.23%
-2.92
-2.92%
-3.01
-72.80%
-3.06
-11.40%
-3.24
-11.45%
-3.14
-7.48%
-3.20
-6.52%
-2.87
6.44%
-1.86
42.64%
Revenue
Q2Q % growth
366.272K
-28.88%
266.332K
-38.21%
288.997K
-19.05%
266.332K
-11.81%
225.859K
-38.34%

-100.00%
5.1M
1,664.73%
18.36M
6,793.65%
44.972M
19,811.57%
EBITDA
Q2Q % growth
-59.521M
-117.44%
-58.43M
-39.87%
-61.376M
-64.68%
-64.025M
-13.27%
-69.822M
-17.31%
N/AN/AN/AN/A
EBIT
Q2Q % growth
-58.886M
-111.78%
-60.688M
-44.89%
-63.371M
-69.04%
-64.338M
-13.20%
-68.375M
-16.11%
-61.06M
-0.61%
-62.669M
1.11%
-56.275M
12.53%
-36.667M
46.37%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth
-2.75
-1.85%
-2.03-0.72-35.55%
Q2 2024
Q2Q % growth
-1.74
76.33%
-2.360.6226.31%
Q1 2024
Q2Q % growth
-2.84
73.33%
-2.12-0.72-33.68%
Q4 2023
Q2Q % growth
-2.97
77.24%
-3.250.288.58%
Q3 2023
Q2Q % growth
-2.70
-181.25%
-5.362.6649.58%
Q2 2023
Q2Q % growth
-7.35
-456.82%
-10.032.6826.70%
Q1 2023
Q2Q % growth
-10.65
-605.30%
-12.021.3711.41%
Q4 2022
Q2Q % growth
-13.05
-903.85%
-12.01-1.04-8.65%
Q3 2022
Q2Q % growth
-0.96
4.00%
-0.90-0.06-6.23%
Q2 2022
Q2Q % growth
-1.32
-50.00%
-1.320.000.32%
Q1 2022
Q2Q % growth
-1.51
-112.68%
-1.33-0.18-13.44%
Q4 2021
Q2Q % growth
-1.30
-49.43%
-1.10-0.20-17.83%
Q3 2021
Q2Q % growth
-1.00
91.74%
-0.95-0.05-4.97%
Q2 2021
Q2Q % growth
-0.88 -0.69-0.19-27.81%
Q1 2021
Q2Q % growth
-0.71 -0.760.056.25%
Q4 2020
Q2Q % growth
-0.87 -0.38-0.49-127.45%
Q3 2020
Q2Q % growth
-12.10 -0.74-11.36-1,525.03%
PRAX Yearly EPS VS EstimatesPRAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 20 -20 -40 -60
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth
302K
-35.47%
301.92K800.03%
Q2 2024
Q2Q % growth
357K
-54.29%
849.66K-492.66K-57.98%
Q1 2024
Q2Q % growth
431K
-36.90%
1.654M-1.223M-73.94%
Q4 2023
Q2Q % growth
515K 51K464K909.80%
PRAX Yearly Revenue VS EstimatesPRAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0.2% -27.26% 0.07% -13.49%
Revenue-1.62% -3.21% 0% 1.92%